cerapedics
-
Biologics
Cerapedics’ i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in Bone Graft Solutions, Now Approved for Expanded Indications for Use
Approval underscores Cerapedics’ commitment to investing in evidence that brings scientific rigor to bone grafting for spinal fusion. WESTMINSTER, Colo., Sept.…
Read More » -
Biologics
Cerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion
If approved, the breakthrough product will bring Cerapedics’ P-15 Peptide to lumbar spine fusion with a TLIF indication, making it…
Read More » -
Biologics
Cerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR®
WESTMINSTER, Colo., Oct. 17, 2023 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone…
Read More » -
Biologics
Cerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products
WESTMINSTER, Colo., July 19, 2023 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair,…
Read More » -
Biologics
Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer
WESTMINSTER, Colo., Oct. 10, 2022 /PRNewswire/ — Cerapedics Inc., a commercial-stage ortho-biologics company dedicated to enhancing the science of bone repair, announced…
Read More » -
Biologics
Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
The ASPIRE study is intended to evaluate the use of P-15L Bone Graft in transforaminal lumbar interbody fusion surgery in…
Read More » -
Biologics
Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery
Data published in ClinicoEconomics and Outcomes Research show that the novel i-FACTOR is not only cost-effective compared to autograft in…
Read More » -
Biologics
Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease
– P-15L Bone Graft is currently being studied in the Company’s ASPIRE IDE clinical trial – WESTMINSTER, Colo., April 29, 2021 /PRNewswire/…
Read More » -
Biologics
Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today…
Read More » -
Biologics
Cerapedics Announces Canadian Approval of its next-generation bone graft
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., September 15, 2020 — Cerapedics, a private…
Read More » -
Biologics
Cerapedics Announces FDA approval of an IDE supplement
WESTMINSTER, Colo., July 22, 2020 — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA)…
Read More » -
Biologics
Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide…
Read More » -
Biologics
Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
WESTMINSTER, Colo., Nov. 18, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has…
Read More » -
Biologics
Cerapedics Announces Expansion of Colorado Headquarters
WESTMINSTER, Colo., July 8, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the expansion of the company’s headquarters located in the Denver metropolitan…
Read More » -
Biologics
Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development
WESTMINSTER, Colo., June 24, 2019 /PRNewswire/ –Cerapedics, a privately-held orthobiologics company, today announced the appointment of Patrick O’Connor as Vice President of Clinical and…
Read More »